Tag:

Dr. Patrick Soon-Shiong

Latest Headlines

Latest Headlines

Biotech billionaire Soon-Shiong plots a second IPO--this time for NantHealth

Biotech billionaire Patrick Soon-Shiong has already laid the foundation for a big IPO to help finance his low-profile oncology R&D player Conkwest. Now he's moving closer to getting his high-profile personalized drug-finding company NantHealth on the market as well.

Billionaire Soon-Shiong arranges a $71M crossover round for Conkwest

Biotech billionaire Patrick Soon-Shiong is pumping $71 million into Conkwest as it preps a move to go public in a $172.5 million IPO.

Biotech billionaire Soon-Shiong steers immuno-oncology player Conkwest to $172.5M IPO

Patrick Soon-Shiong thinks he can beat CAR-Ts in the clinic. And after quietly taking control of a small biotech named Conkwest, the biotech billionaire is now floating a $172.5 million IPO in a sizzling hot market to raise new funds for the midstage program that lies ahead.

Soon-Shiong raises $75M for another oncology player in his murky empire

It seems not a month goes by without billionaire entrepreneur Patrick Soon-Shiong striking a deal to expand his sprawling family of cancer-focused startups. This time, the recently launched NantCell has raised $75 million in equity, pressing forward in immuno-oncology with some in-licensed treatments.

Sorrento dives into immuno-oncology under Soon-Shiong's shadow

Sorrento Therapeutics, a frequent partner of billionaire biotech entrepreneur Patrick Soon-Shiong, launched a new subsidiary to advance its take on CAR-T therapies for cancer, taking a page from its patron as it tosses more and more irons in the R&D fire.

Soon-Shiong bets $90M on Sorrento's next-gen Abraxane with $1.2B on the line

NantWorks, the nebulous empire of biotech billionaire Patrick Soon-Shiong, is handing over $90 million to partner Sorrento Therapeutics in exchange for a Phase III cancer drug heralded as a successor to the blockbuster Abraxane.

Soon-Shiong raises another $100M for his cancer-focused biotech

Billionaire entrepreneur Patrick Soon-Shiong has raised $100 million for one of the many offshoots of his NantWorks conglomerate, working to duplicate the success of the targeted cancer drug that helped build his empire.

Soon-Shiong's NantWorks deepens its immuno-oncology ties with Sorrento

Billionaire biotech entrepreneur Patrick Soon-Shiong is expanding his company's relationship with Sorrento Therapeutics, promising $110 million in cash and equity in exchange for the rights to some cancer-fighting immunotherapies.

Ex-employees say Soon-Shiong's Big Data venture is a fraud

NantHealth, an arm of billionaire physician and biotech entrepreneur Patrick Soon-Shiong's empire, promises to improve cancer diagnostics through a marriage of genomics and high-speed computing. But behind its sleek marketing campaign and Soon-Shiong's bravura, the company is misleading customers and putting patients at risk, according to a lawsuit filed by two former employees.

Soon-Shiong's new biotech pairs up with Amgen on a cancer immunotherapy

Billionaire physician and biotech entrepreneur Patrick Soon-Shiong has launched a company devoted to immuno-oncology, licensing a treatment from Amgen to get rolling in the field.